Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 1914204 approvals9 trials

Tego Science, Inc.

Official website

Tego Science makes cell therapies Holoderm and Rosmir, and sells the 3D skin model Neoderm for CDMO and animal-alternative testing.

As of 2026-10-10, Tego Science, Inc. has 1 Korean MFDS device approval, 3 Korean MFDS drug approvals, 12 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2001 and listed on KOSDAQ in 2014, Tego Science is a biotech company that develops and manufactures cell therapies using cell culture technology. It sells the autologous cell therapies Holoderm, approved in 2002, and the wrinkle-improvement therapy Rosmir, and commercializes the 3D cultured skin product Neoderm for animal-alternative testing. It holds 3 of Korea's 16 approved cell therapy products (5 of 19 indications), runs domestic Phase 2b/3 and US Phase 2 trials for a rotator cuff tear therapy, and is expanding into CDMO services across the full development cycle.

Products & technology

  • HolodermAutologous cell therapy
  • RosmirAutologous cell therapy for wrinkle improvement
  • Neoderm3D cultured skin used for animal-alternative testing and drug candidate efficacy prediction

Regulatory approvals

data.go.kr

3 Korean MFDS drug approvals · 2021 / 1 Korean MFDS device approvals · 2025

  • MFDSDressing, fluid-impermeable film2025-03-04
    Product approval · Class 2제인 25-4163 호
  • MFDS drugHoloderm2021-08-27
    Drug · Prescription · Approval202106197
  • MFDS drugKaloderm2021-08-27
    Drug · Prescription · Approval202106210
  • MFDS drugRosmir2021-08-24
    Drug · Prescription · Approval202106147

Clinical trials

data.go.kr

9 MFDS clinical trial authorisations · 2012–2024 (Phase 1 3 · Phase 2b/3 1 · Phase 1/2 1 · Phase 3 1 · Phase 1/3 1)

  • Phase 1TPX-1152024-07-25

    1 trial site

  • Phase 2b/3TPX-1152023-05-08

    2 trial sites

  • Phase 1/2TPX-1152020-03-25

    2 trial sites

  • Phase 3TPX-1052018-11-15

    4 trial sites

  • Phase 1/3TPX-1142018-03-08

    2 trial sites

  • Phase 1TPX-1052015-09-17

    2 trial sites

  • Phase 2bTPX-1112013-11-14

    2 trial sites

  • Phase 1TPX-1022013-05-16

    1 trial site

  • Phase 2TPX-1032012-10-11

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

주름개선용 동종유래 세포치료제 · 주름개선 · 국내 임상신청 준비 중 · Developed to improve commercial viability of the approved autologous therapy Rosmir

건질환(회전근개 파열 등) 치료용 자기유래·동종유래 세포치료제 · 회전근개 파열 등 건질환 · 국내 임상2b/3상 진행 중, 미국 임상2상(IND 승인) 진행 중 · Extension of R&D into musculoskeletal disease

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched
Show 2 more publications

Patents

KIPRIS · applicant-matched
Show 31 more patents

AI reads

MAA server logs · IP-verified
68
Times AI engines pulled Tego Science, Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

67
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 1
Last 7 days
61
live 1
Last 30 days
68
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot58
  • PerplexityPerplexityBot4
  • GoogleGoogleOther2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Tego Science, Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

HANS BIOMED CORPORATION1 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

DONGWHA PHARM.CO.,LTD1 shared

Dongwha Pharm, founded in 1897 and KOSPI-listed in 1976, is a diversified company centered on pharmaceuticals.

WonIk Co.,LTD1 shared

WonIk, founded in 1983 and KOSDAQ-listed in 1997, operates pressure sensor, dermo-cosmetic, and medical device distribution businesses.

BIO-FD&C CO.,LTD.1 shared

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

DaehanPharmaceutical1 shared

Daehan Pharmaceutical, founded in 1963 and KOSDAQ-listed in 1994, manufactures intravenous fluid pharmaceuticals.

PharmaResearch Co., Ltd.1 shared

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

Humedix Co., Ltd.1 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

Wonbiogen Co.,Ltd.1 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

Dong-A Socio Holdings Co.,Ltd1 shared

Founded 1949, KOSPI-listed 1970, Dong-A Socio Holdings makes Bacchus and pharma/non-pharma goods, allied with Meiji Seika on biosimilars.

KOLMAR KOREA CO.,LTD1 shared

Founded and listed on KOSPI in 2012 upon spin-off from the former Kolmar Korea, KOLMAR KOREA runs cosmetics ODM, prescription drugs, and packaging.

Keeps Biopharma Inc.1 shared

Founded in 2000 and listed on KOSDAQ in 2017, Keeps Biopharma transitioned from OLED equipment to pharmaceuticals through its 2025 merger with Korea Global Pharm.

DongKookPharmaceuticalCo.,Ltd.1 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition